Prot #AG120-C-001: A Phase 1, Multicenter, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Orally Administered AG-120 in Subjects with Advanced Hematologic Malignancies with an IDH1 Mutation

Project: Research project

Project Details

StatusFinished
Effective start/end date7/31/14 → 7/31/22

Funding

  • INC Research, LLC (Prot #AG120-C-001)
  • Agios Pharmaceuticals, Inc. (Prot #AG120-C-001)